ABSTRACT
INTRODUCTION
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently recommended as the standard first line treatment for non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations. The majority of clinical data regarding EGFR-TKIs in EGFR-mutant population are derived from lung adenocarcinoma (ADC).
The percentage of EGFR mutations in lung squamous cell carcinoma (SQC) is only about 10% in persons of Asian descent [1] and < 5% in western countries [2] . Our literature review only identified small case series studies and case reports about the sensitivity of EGFR-TKI in SQC with EGFR mutation in the literature. The objective response rates (ORR), disease control rates (DCR) and median progression free survival rates (PFS) in
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these studies were 25.0-26.7%, 66.7-71.0% and 1.4-6.3 months, respectively [3] [4] [5] . EGFR-TKI seems to be less effective in SQC than in ADC and the role of EGFR-TKI in EGFR-mutant SQC remains to be debated.
We therefore performed a matched-pair case-control study retrospectively to investigate the different efficacy of EGFR-TKI in EGFR-mutant SQC and ADC patients from 3 cancer centers. Subsequently, a pooled analysis that included our own data and data obtained from previous studies at other institutions was carried out to evaluate the role of EGFR-TKIs in EGFR-mutant SQC, which represents the largest study to our knowledge of this patient cohort.
RESULTS

Patient characteristics
The initial matched-pair case-control study included 88 NSCLC patients from 3 cancer centers (44 SQC and 44 ADC). Among them, 52 patients were male, 46 patients were non-smokers and 62 patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. The median age was 56 years (range: 
Response and survival
In the matched-pair case-control study, the median follow-up time for all the 88 patients was 41.1 months (range, 0.5-61.0 months) upto the study closing date of December 30, 2015 . For SQC patients 19 had partial responses (PR), 15 had stable disease (SD) and 10 had progressive disease (PD) after EGFR-TKI treatment, which resulted in ORR of 43.2% and DCR 77.3%. For ADC patients, ORR was 54.5% and DCR was 100%, including 24 PR and 20 SD. There was no significant difference of ORR between SQC and ADC groups (43.2% versus 54.5%, P = 0.290), but SQC group had lower DCR than ADC group (77.3% vs. 100%, P = 0.001). By the time of the final analysis, 9 patients had not experienced progression and 20 patients were still alive in both SQC and ADC group. The median PFS of all the patients was 10.7 months (95% CI: 8.38-13.03). SQC group had significant shorter PFS than ADC group (5.1 vs. 13.0 months, p = 0.000) (Figure 1 ). The median OS of all the patients was 22.7 months (95% CI: 20.53-24.87). The OS of SQC group and ADC group had statistical significant difference (17.2 vs. 23.6 months, p = 0.027) ( Figure 2 ).
In the pooled analysis, tumor response was identified in 71 patients from the published reports. The ORR and DCR were 39.1% and 71.3%, respectively, of all the 115 SQC patients. PFS was identified in 28 patients from the published reports. The PFS analysis was performed in 72 SQC patients. The median PFS of all the patients was 5.6 months (95% CI: 3.93-7.27 months). Better PS (ECOG 0-1) was associated with better PFS both in univariate and multivariate analysis (Table 3) . OS was extracted in 26 patients from the reports. The OS analysis was performed in 70 SQC patients. The median OS of all the patients was 15.0 months (95% CI: 8.15-21.85 months). The patients treated with erlotinib had longer OS than those treated with gefitinib both in univariate and multivariate analysis (Table 4) .
DISCUSSION
In this study, we investigated the efficacy of EGFR-TKI treatment in lung SQC harboring EGFR mutation. We found that the ORR, DCR, PFS and OS of EGFR-mutated lung SQC treated with EGFR-TKI were 39.1%, 71.3%, 5.6 months and 15.0 months, respectively.
In our multicenter matched-pair case-control study, SQC patients had significant lower DCR, shorter PFS and OS than ADC patients. Although the mechanism behind the efficacy difference between ADC and SQC is unclear, there is now evidence from previous studies, including the TCGA study, revealing a number of genomic differences between ADC and SQC [30] . Gene amplifications of 3q including SOX2, TP63, PIK3CA, and EPHB3 were observed in as many as 86% of SQC samples but only 21% of adenocarcinoma samples [31] . Allelic losses [32] or hypermethylations [33] on the 3p region has been observed more frequently in tumors with a squamous histology compared with adenocarcinoma, involving some tumor suppressor genes such as RASSF1A, FUS1, www.impactjournals.com/oncotarget VHL, and FHIT. Meanwhile activations of other signaling pathways, such as ERBB2 [34] and PIK3CA [35, 36] may mediate resistance of lung cancers to EGFR-targeting therapies. We theorize that multiple signaling pathways are activated in the development and progression of lung SQC, while ADC may depend on a key pathway, such as EGFR, ALK or ROS-1. Accordingly, the efficacy is inferior in SQC patients when therapy to block a single pathway is used. However, we feel that the utility of EGFR-TKI in SQC should be studied further. We found that SQC patients treated with EGFR-TKI had the similar ORR to ADC patients. Approximately one third of the EGFR-mutant SQC patients obtained a PFS longer than 6 months and an OS longer than 1 year which may be due to the efficacy of EGFR-TKIs. Some EGFRmutant SQC could benefit from EGFR-TKI treatment and EGFR-TKI is an important intervention for these patients.
Further study is needed to identify these patients that may benefit.
The incidence of EGFR mutations in lung SQC may differ in Asian and non-Asian populations. Previous reports revealed that the incidence of EGFR mutations in western populations is low, ranging from 0% to 3.6% [37, 38] . However, the frequency of EGFR mutation is much higher in Asian populations [1, 3, 5] . The incidence of SQC harboring sensitive EGFR mutation was 13.3% (63/249) in Japan [3] and 17.8% (109/614) in another study from Chin a [5] . In our center, the EGFR-mutant incidence of lung SQC was 6.1% (22/359). Therefore, we consider routine EGFR mutation testing for all Asian lung SQC patients.
This study is a retrospective multiple center and comprehensive review of the published literature. The validation of the results relies on higher level evidence, such as randomized controlled trials. Although this study includes all available data we identified in the literature, the sample size is still insufficient. Large sample studies would help generate more robust conclusions.
In conclusion, EGFR-TKI was less effective in EGFRmutant SQC than in ADC but still has clinical benefit for some SQC patients. We present the largest pooled analysis to identify the clinical profiles of EGFR-TKI application for EGFR-mutant SQC, which may provide valuable information for treatment selection.
MATERIALS AND METHODS
Patients
From January 2004 to October 2015, 44 EGFRmutant SQC patients treated with EGFR-TKI (gefitinib 250 mg/day, erlotinib 150mg/day or icotinib 125 mg tid) were selected from 3 cancer centers including the cancer centers of West China Hospital, Sichuan University, Sun Yat-sen University Cancer Center and Cancer Hospital of Sichuan Province, China. The patients were diagnosed by bronchofiberscope or percutaneous lung biopsy. The pathological diagnosis was confirmed by light microscopy and immunohistochemistry (IHC) and verified by stains for P40, thyroid transcription factor (TTF)-1 and Napsin A (negative, positive, and negative, respectively). EGFR mutations were identified by real-time Amplification Refractory Mutation System (ARMS) quantitative PCR analysis using AmoyDxTM EGFR Mutation Detection Kit (Amoy Diagnostics Co., LTD, China) and EGFR Scorpion ARMS Kit (DxS Ltd, Manchester, UK). All patients have the confirmed status of EGFR mutation.
EGFR-mutant ADC patients were pair matched to selected SQC patients from our lung cancer database according to seven variables: gender (male, female); age (< 70 years, ≥ 70 years); smoking history (non-smokers, current or former smokers); ECOG PS (< 2, ≥ 2); status of EGFR mutation (19-DEL, L858R, G719X/S768I); drugs of EGFR-TKI (gefitinib, erlotinib, icotinib) and prior chemotherapy (0, ≥ 1). Clinical data of each patients was well recorded.
Tumor response was determined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The treatment response was evaluated 1 month after the initiation of EGFR-TKI therapy and then every 2 months. This retrospective analysis was approved by the Institutional Review Board of the above stated hospitals and signed consent was obtained from each patient for the use of tissue in molecular analysis.
In order to further investigate the efficacy of EGFR-TKI for EGFR-mutant lung SQC, we performed a systematic search of the PUBMED database to identify all clinical trials and case reports that contained EGFR-mutant SQC patients 
Statistical analysis
PFS was calculated from the date of initiation of EGFR-TKIs to the time of disease progression. Overall survival (OS) was calculated from the time of beginning receiving EGFR-TKIs until the date of death. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was performed using Cox regression test. Comparison of the qualitative data was done by Pearson χ 2 or the Fisher exact test. P values < 0.05 was considered statistically significant. All statistical analyses were performed with SPSS 22.0.
